The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy
- 20 January 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 117 (3), 1005-1013
- https://doi.org/10.1182/blood-2010-07-297713
Abstract
Two major pathways contribute to Ras-proximate-1–mediated integrin activation in stimulated platelets. Calcium and diacyglycerol-regulated guanine nucleotide exchange factor I (CalDAG-GEFI, RasGRP2) mediates the rapid but reversible activation of integrin αIIbβ3, while the adenosine diphosphate receptor P2Y12, the target for antiplatelet drugs like clopidogrel, facilitates delayed but sustained integrin activation. To establish CalDAG-GEFI as a target for antiplatelet therapy, we compared how each pathway contributes to thrombosis and hemostasis in mice. Ex vivo, thrombus formation at arterial or venous shear rates was markedly reduced in CalDAG-GEFI−/− blood, even in the presence of exogenous adenosine diphosphate and thromboxane A2. In vivo, thrombosis was virtually abolished in arterioles and arteries of CalDAG-GEFI−/− mice, while small, hemostatically active thrombi formed in venules. Specific deletion of the C1-like domain of CalDAG-GEFI in circulating platelets also led to protection from thrombus formation at arterial flow conditions, while it only marginally increased blood loss in mice. In comparison, thrombi in the micro- and macrovasculature of clopidogrel-treated wild-type mice grew rapidly and frequently embolized but were hemostatically inactive. Together, these data suggest that inhibition of the catalytic or the C1 regulatory domain in CalDAG-GEFI will provide strong protection from athero-thrombotic complications while maintaining a better safety profile than P2Y12 inhibitors like clopidogrel.Keywords
This publication has 46 references indexed in Scilit:
- Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseasesBritish Journal of Pharmacology, 2010
- Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapyProceedings of the National Academy of Sciences of the United States of America, 2009
- PKCα regulates platelet granule secretion and thrombus formation in miceJCI Insight, 2009
- Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivoThe Journal of Experimental Medicine, 2007
- Talin is required for integrin-mediated platelet function in hemostasis and thrombosisThe Journal of Experimental Medicine, 2007
- Differential membrane binding and diacylglycerol recognition by C1 domains of RasGRPsBiochemical Journal, 2007
- Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type IIIJCI Insight, 2007
- Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury modelJCI Insight, 2007
- IntegrinsCell, 2002
- Rap1 signalling: adhering to new modelsNature Reviews Molecular Cell Biology, 2001